Ruxolitinib and Tobacco and smoking interaction
Ruxolitinib and Tobacco and smoking: the Ruxolitinib prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Ruxolitinib (JAKAFI) label · effective 2026-07-20
Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers.
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with JAKAFI/JAKAFI XR particularly in patients who are current or past smokers and patients with other cardiovascular risk factors.
Patients who are current or past smokers are at additional increased risk.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.